Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
1959 1
1966 1
1967 1
1968 3
1970 1
2001 1
2006 1
2008 1
2010 1
2011 1
2012 1
2013 1
2014 1
2018 1
2019 2
2020 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial.
Hanrahan JP, de Boer IH, Bakris GL, Wilson PJ, Wakefield JD, Seferovic JP, Chickering JG, Chien YT, Carlson K, Cressman MD, Currie MG, Milne GT, Profy AT. Hanrahan JP, et al. Among authors: wakefield jd. Clin J Am Soc Nephrol. 2020 Dec 31;16(1):59-69. doi: 10.2215/CJN.08410520. Epub 2020 Dec 16. Clin J Am Soc Nephrol. 2020. PMID: 33328269 Free PMC article. Clinical Trial.
An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension.
Hanrahan JP, Seferovic JP, Wakefield JD, Wilson PJ, Chickering JG, Jung J, Carlson KE, Zimmer DP, Frelinger AL 3rd, Michelson AD, Morrow L, Hall M, Currie MG, Milne GT, Profy AT. Hanrahan JP, et al. Among authors: wakefield jd. Diabetologia. 2020 Apr;63(4):733-743. doi: 10.1007/s00125-019-05062-x. Epub 2019 Dec 19. Diabetologia. 2020. PMID: 31858186 Free PMC article. Clinical Trial.
A Randomized, Placebo-Controlled, Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Soluble Guanylate Cyclase Stimulator Praliciguat in Healthy Subjects.
Hanrahan JP, Wakefield JD, Wilson PJ, Mihova M, Chickering JG, Ruff D, Hall M, Milne GT, Currie MG, Profy AT. Hanrahan JP, et al. Among authors: wakefield jd. Clin Pharmacol Drug Dev. 2019 Jul;8(5):564-575. doi: 10.1002/cpdd.627. Epub 2018 Nov 13. Clin Pharmacol Drug Dev. 2019. PMID: 30422390 Clinical Trial.
Pharmacokinetics, mass balance, tissue distribution, metabolism, and excretion of praliciguat, a clinical-stage soluble guanylate cyclase stimulator in rats.
Banijamali AR, Carvalho AE, Wakefield JD, Germano P, Barden TC, Tobin JV, Zimmer DP, Masferrer JL, Profy AT, Currie MG, Todd Milne G. Banijamali AR, et al. Among authors: wakefield jd. Pharmacol Res Perspect. 2020 Apr;8(2):e00579. doi: 10.1002/prp2.579. Pharmacol Res Perspect. 2020. PMID: 32314550 Free PMC article.
Olinciguat, an Oral sGC Stimulator, Exhibits Diverse Pharmacology Across Preclinical Models of Cardiovascular, Metabolic, Renal, and Inflammatory Disease.
Zimmer DP, Shea CM, Tobin JV, Tchernychev B, Germano P, Sykes K, Banijamali AR, Jacobson S, Bernier SG, Sarno R, Carvalho A, Chien YT, Graul R, Buys ES, Jones JE, Wakefield JD, Price GM, Chickering JG, Milne GT, Currie MG, Masferrer JL. Zimmer DP, et al. Among authors: wakefield jd. Front Pharmacol. 2020 Apr 8;11:419. doi: 10.3389/fphar.2020.00419. eCollection 2020. Front Pharmacol. 2020. PMID: 32322204 Free PMC article.
Fatty acid amide hydrolase (FAAH) inhibition reduces L-3,4-dihydroxyphenylalanine-induced hyperactivity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned non-human primate model of Parkinson's disease.
Johnston TH, Huot P, Fox SH, Wakefield JD, Sykes KA, Bartolini WP, Milne GT, Pearson JP, Brotchie JM. Johnston TH, et al. Among authors: wakefield jd. J Pharmacol Exp Ther. 2011 Feb;336(2):423-30. doi: 10.1124/jpet.110.169532. Epub 2010 Oct 21. J Pharmacol Exp Ther. 2011. PMID: 20966038
Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation.
Busby RW, Kessler MM, Bartolini WP, Bryant AP, Hannig G, Higgins CS, Solinga RM, Tobin JV, Wakefield JD, Kurtz CB, Currie MG. Busby RW, et al. Among authors: wakefield jd. J Pharmacol Exp Ther. 2013 Jan;344(1):196-206. doi: 10.1124/jpet.112.199430. Epub 2012 Oct 22. J Pharmacol Exp Ther. 2013. PMID: 23090647
19 results